Product Information
RIVASTIGMINE 13.3 MG/24HR PTCH is a generic product labeled by NorthStar Rx LLC, priced at $1.8531 per EA under NDC 16714011702. Its NADAC has been published 312 times since Jul 8, 2020.
Strength
13.3 mg/24h
Manufacturer
NorthStar Rx LLCNDC
16714011702
Classification
Generic
Dosage Form
PATCH, EXTENDED RELEASE
Route
TRANSDERMAL
Last Updated
6/17/2026
Active Ingredients
RIVASTIGMINEApproval Type
Generic (ANDA)
FDA Application
ANDA206318On Market Since
10/1/2019
Pharmacological Classes
Price Statistics
The NADAC for RIVASTIGMINE 13.3 MG/24HR PTCH has been published 312 times since Jul 8, 2020, and over the history we have for it it has declined 48.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.8531 per EA |
|---|---|
| All-time high | $4.1005 (Nov 11, 2020) |
| All-time low | $1.6436 (Apr 17, 2024) |
| 52-week high | $2.0633 |
| 52-week low | $1.8531 |
| Median price | $2.2778 |
| Average price | $2.5627 |
| Largest weekly change | -33.3% (Apr 17, 2024) |
| Weeks tracked | 312 |
| Tracking since | Jul 8, 2020 |
Generic Alternatives
The matcher finds 3 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 3 manufacturers (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of RIVASTIGMINE 13.3 MG/24HR PTCH?
The current National Average Drug Acquisition Cost (NADAC) for RIVASTIGMINE 13.3 MG/24HR PTCH, manufactured by NorthStar Rx LLC, is $1.8531 per EA (NDC 16714011702), effective Jun 24, 2026.
How has the price of RIVASTIGMINE 13.3 MG/24HR PTCH changed over time?
Over the history we have for it, the NADAC for RIVASTIGMINE 13.3 MG/24HR PTCH has declined 48.2%. It has been tracked across 312 weekly CMS publications since Jul 8, 2020.
What are the highest and lowest recorded NADAC prices for RIVASTIGMINE 13.3 MG/24HR PTCH?
Since Jul 8, 2020, the NADAC for RIVASTIGMINE 13.3 MG/24HR PTCH has ranged from a low of $1.6436 (Apr 17, 2024) to a high of $4.1005 (Nov 11, 2020), with a median of $2.2778 per EA.
Are there cheaper alternatives to RIVASTIGMINE 13.3 MG/24HR PTCH?
3 NADAC-published products share the same active ingredient, strength, and dosage form as RIVASTIGMINE 13.3 MG/24HR PTCH, but none are currently priced below it.
Who manufactures RIVASTIGMINE 13.3 MG/24HR PTCH?
RIVASTIGMINE 13.3 MG/24HR PTCH (NDC 16714011702) is labeled by NorthStar Rx LLC, and CMS classifies it as a generic product.
Related Drugs
Same classification